SIRT6 can reportedly promote NSCLC progression and migration: SIRT6 could drive epithelial‐to‐mesenchymal transition by transrepression the expression of KLF4,18 and SIRT6 knockdown could improve paclitaxel sensitivity.10 Here, SIRT6 is linked to non-small cell lung carcinoma.